In this older patient with T2DM, HFpEF, and other comorbidities, which class of medication is most appropriate--and guideline-recommended?
Dupilumab Cardiometabolic Safety in Real-World Study of Atopic Dermatitis Supports Clinical Trial Evidence
Treatment of AD with dupilumab, compared with cyclosporine and methotrexate, was associated with significantly reduced risk of a wide range of CV outcomes at 1 year.
Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care
Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.
Ozempic Approval Expanded to Include Patients with T2D and CKD: Daily Dose
Your daily dose of the clinical news you may have missed.
Obesity & Type 2 Diabetes: An Expert Discussion
In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.
FDA Accepts BLA for Lerodalcibep, Novel PCSK9 Inhibitor to Lower LDL-C
The FDA set a PDUFA action date of December 12, 2025 for lerodalcibep, according to LIB Therapeutics.
Diabetes Caution: FDA Warns of Risk of Missing Critical Alerts from Smartphone-Compatible Diabetes Devices
Hardware or software changes as well as user adjustments may disable or mute alerts for elevated glycemia, medication use, and other diabetes management essentials, the agency said.